ABSTRACT
BACKGROUND: Suppression of the renin-angiotensin-aldosterone system (RAAS) is therapeutically valuable in chronic heart failure (CHF). RAAS inhibition can be achieved in a number of ways though an orally active renin inhibitor (RI) has never been studied before. We describe the neurohumoral effects of an RI. METHODS AND RESULTS: 27 patients with NYHA class II or III CHF and an ejection fraction Subject(s)
Amides/therapeutic use
, Fumarates/therapeutic use
, Heart Failure/drug therapy
, Renin/antagonists & inhibitors
, Aged
, Aldosterone/blood
, Analysis of Variance
, Angiotensin II/blood
, Angiotensin-Converting Enzyme Inhibitors/therapeutic use
, Chronic Disease
, Female
, Heart Failure/blood
, Humans
, Male
, Middle Aged
, Natriuretic Peptide, Brain/blood
, Ramipril/therapeutic use
, Renin/blood
, Statistics, Nonparametric
, Treatment Outcome
